Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 1
Submit an article Journal homepage
618
Views
61
CrossRef citations to date
0
Altmetric
Research Article

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

Qaiser BashirDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
,
Nina ShahDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Simrit ParmarDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Wei WeiDepartment of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Gabriela RondonDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Donna M. WeberDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Michael WangDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Robert Z. OrlowskiDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Sheeba K. ThomasDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Jatin ShahDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Sofia R. QureshiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Yvonne T. DinhDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Uday PopatDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Paolo AnderliniDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Chitra HosingDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Sergio GiraltDepartment of Blood and Marrow Transplantation, Memorial Sloan Kettering Cancer Center, New York, NY, USA
,
Richard E. ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
&
Muzaffar H. QazilbashDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
 show all
Pages 118-122 | Received 09 May 2011, Accepted 17 Jul 2011, Published online: 24 Aug 2011

References

  • Blade J, Rosinol L, Cibeira MT, . Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood; 115: 3655–3663.
  • Attal M, Harousseau JL, Stoppa AM, . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
  • Child JA, Morgan GJ, Davies FE, . High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.
  • Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009;360: 2645–2654.
  • Facon T, Mary JY, Hulin C, . Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209–1218.
  • Kumar SK, Dingli D, Lacy MQ, . Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008;83:614–617.
  • Badros A, Barlogie B, Siegel E, . Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:600–607.
  • Qazilbash MH, Saliba RM, Hosing C, . Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 2007;39:279–283.
  • Durie BG, Harousseau JL, Miguel JS, . International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
  • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
  • Avet-Loiseau H, Attal M, Moreau P, . Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–3495.
  • Fonseca R, Blood E, Rue M, . Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101: 4569–4575.
  • Hanamura I, Stewart JP, Huang Y, . Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108: 1724–1732.
  • Fonseca R, Barlogie B, Bataille R, . Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64: 1546–1558.
  • Ludwig H, Bolejack V, Crowley J, . Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010;28:1599–1605.
  • Palumbo A, Triolo S, Argentino C, . Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248–1253.
  • Siegel DS, Desikan KR, Mehta J, . Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93: 51–54.
  • Jantunen E, Kuittinen T, Penttila K, . High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or = 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006;37:917–922.
  • Sirohi B, Powles R, Treleaven J, . The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000;25:533–539.
  • Palumbo A, Bringhen S, Petrucci MT, . Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052–3057.
  • Dumontet C, Ketterer N, Espinouse D, . Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplant 1998;21:1037–1041.
  • Palumbo A, Gay F, Falco P, . Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800–807.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.